Vitro Biopharma

Vitro Biopharma is a US-based biotech developing allogeneic cell therapies derived from umbilical cord Wharton's jelly. Its core technology involves a proprietary culture media (MSC-Gro) and a cGMP/ISO-certified manufacturing process designed for scalability and cost advantage. The company is led by a team with expertise in finance, science, and regulatory affairs, and is primarily focused on advancing its lead program through clinical development for autoimmune and inflammatory conditions.

Proprietary platform for isolating and expanding mesenchymal stem cells (MSCs) from Wharton's jelly of umbilical cords using a specialty culture media (MSC-Gro), supported by scalable cGMP/ISO-certified manufacturing.

Vitro Biopharma competes in the broad and competitive field of mesenchymal stem cell (MSC) therapeutics, which includes numerous private and public companies developing MSC therapies for inflammatory conditions. Key differentiators claimed are its Wharton's jelly source and proprietary manufacturing process, but it likely trails companies with more advanced clinical programs.